RUNX3 Promotes the Tumorigenic Phenotype in KGN, a Human Granulosa Cell Tumor-Derived Cell Line
Authors:
- Huachen ChenHCHuachen Chen
- Powel CrosleyPCPowel Crosley
- Abul K. AzadAAAbul K. Azad
- Nidhi GuptaNGNidhi Gupta
- Nisha GokulNGNisha Gokul
- Zhihua XuZXZhihua Xu
- Michael WeinfeldMWMichael Weinfeld
- Lynne-Marie PostovitLPLynne-Marie Postovit
- Stephanie A. PangasSPStephanie A. Pangas
- Mary M. HittMHMary M. Hitt
- YangXin FuYFYangXin Fu
Open Access
- 15 July 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (14) , 3471
Abstract
Granulosa cell tumors of the ovary (GCT) are the predominant type of ovarian sex cord/stromal tumor. Although prognosis is generally favorable, the outcome for advanced and recurrent GCT is poor. A better understanding of the molecular pathogenesis of GCT is critical to developing effective therapeutic strategies. Here we have examined the potential role of the runt-related transcription factor RUNX3. There are only two GCT cell lines available. While RUNX3 is silenced in the GCT cell line KGN cells, it is highly expressed in another GCT cell line, COV434 cells. Re-expression of RUNX3 promotes proliferation, anchorage-independent growth, and motility in KGN cells in vitro and tumor formation in mice in vivo. Furthermore, expression of a dominant negative form of RUNX3 decreases proliferation of COV434 cells. To address a potential mechanism of action, we examined expression of cyclin D2 and the CDK inhibitor p27Kip1, two cell cycle regulators known to be critical determinants of GCT cell proliferation. We found that RUNX3 upregulates the expression of cyclin D2 at the mRNA and protein level, and decreases the level of the p27Kip1 protein, but not p27Kip1 mRNA. In conclusion, we demonstrate that RUNX proteins are expressed in GCT cell lines and human GCT specimens, albeit at variable levels, and RUNX3 may play an oncogenic role in a subset of GCTs.Keywords
Funding Information
- Women and Children's Health Research Institute (N/A)
- Granulosa Cell Tumour Research Foundation (N/A)
- National Institutes of Health (CA138628, HD085994)
- P30 Cancer Center support grant (NCI-CA125123)
- Alberta Cancer Foundation (N/A)
This publication has 52 references indexed in Scilit:
- Granulosa cell tumor of ovary: A systematic review of recent evidenceEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2018
- Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutationPLOS ONE, 2017
- Pathogenesis and treatment of adult-type granulosa cell tumor of the ovaryAnnals of Medicine, 2017
- Adult granulosa cell tumours of the ovaryCurrent Opinion in Oncology, 2014
- The role of FOXL2 in the pathogenesis of adult ovarian granulosa cell tumoursGynecologic Oncology, 2014
- Les tumeurs de la granulosa de l’ovaireBulletin du Cancer, 2014
- Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovaryBritish Journal of Cancer, 2013
- Molecular Pathogenesis of Granulosa Cell Tumors of the OvaryEndocrine Reviews, 2012
- Mutation ofFOXL2in Granulosa-Cell Tumors of the OvaryNew England Journal of Medicine, 2009
- Management of Ovarian Stromal Cell TumorsJournal of Clinical Oncology, 2007